The use of anti-CD30 CAR T cells was recently studied in a phase I clinical trial on 9 patients with refractory or relapsed HD and anaplastic large cell lymphoma (ALCL) [66]. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.